Francesca Palandri/LinkedIn
Sep 26, 2026, 15:55
Francesca Palandri: The R-NAT Score Developed in Ruxolitinib-Treated MF Patients
Francesca Palandri, Hematologist at IRCCS Policlinico di Sant’Orsola – University Hospital of Bologna, shared a post on LinkedIn:
“Can we predict thrombosis in myelofibrosis patients treated with ruxolitinib?
- At the SIE – Italian Society of Hematology 2026 Congress I presented the R-NAT score, developed in 1,126 ruxolitinib-treated MF patients from the RUX-MF study:
- Current models fall short in MF: IPSET-T and the conventional binary model barely separated patients by risk (C-index 0.53–0.55).
- NLR is the missing inflammatory piece: a baseline neutrophil-to-lymphocyte ratio above 3.53 (the upper limit of normal) independently doubled the risk of thrombosis (SHR 2.17), even among patients already classed as high-risk.
- A simple, validated 3-variable score: R-NAT combines age, prior thrombosis and NLR >3.53. It separates patients into three groups with 5-year thrombosis-free survival of 97.4 percent, 89.1 percent and 77.9 percent (C-index 0.72). Special thanks to Massimo Breccia and Alessandro Laganà for the external validation.
Many thanks to all the RUX-MF investigators, my Colleagues Filippo Branzanti, Chiara Sartor, Alessandra Dedola, to IRCCS Sant’Orsola Hospital – University Hospital of Bologna, Alma Mater Studiorum – University of Bologna, and to AIL Bologna for their constant support.”
Stay updated with Hemostasis Today.
-
Sep 26, 2026, 16:41Matthew Smeds: Management of Thoracic Endograft Thrombosis and Mesenteric Embolization
-
Sep 26, 2026, 16:04Isabelle Feldhaus: What the New ASH Iron Deficiency Guidance Means for Care
-
Sep 26, 2026, 15:49Alex Ehsan: Antiphospholipid Syndrome – A Practical Guide
-
Sep 26, 2026, 15:42Michael Tadao Inouye: The Next Frontier in Genomic Population Health
-
Sep 26, 2026, 15:32Katariina Öörni: Familial Hypercholesterolaemia in Children Why Early Diagnosis Matters
-
Sep 26, 2026, 15:30P-Selectin as a Therapeutic Target in Thrombosis
-
Sep 26, 2026, 15:27Berkan Kurt: The Role of Biomarkers in Cardiovascular Prevention
-
Sep 26, 2026, 15:21Consuela A. Albright: Five Concrete Ways Steps to Advocate for Sickle Cell Disease
-
Sep 26, 2026, 15:09New ASH Funding Opportunities for Hematology Researchers